NZ512850A - Treatment of papillomavirus infections - Google Patents

Treatment of papillomavirus infections

Info

Publication number
NZ512850A
NZ512850A NZ512850A NZ51285099A NZ512850A NZ 512850 A NZ512850 A NZ 512850A NZ 512850 A NZ512850 A NZ 512850A NZ 51285099 A NZ51285099 A NZ 51285099A NZ 512850 A NZ512850 A NZ 512850A
Authority
NZ
New Zealand
Prior art keywords
treatment
papillomavirus infections
therapeutic vaccine
protein
hpv
Prior art date
Application number
NZ512850A
Other languages
English (en)
Inventor
Jian Zhou
Ian Frazer
Original Assignee
Univ Queensland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Queensland filed Critical Univ Queensland
Publication of NZ512850A publication Critical patent/NZ512850A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ512850A 1998-12-11 1999-12-13 Treatment of papillomavirus infections NZ512850A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP7653A AUPP765398A0 (en) 1998-12-11 1998-12-11 Treatment of papillomavirus infections
PCT/AU1999/001108 WO2000035478A1 (en) 1998-12-11 1999-12-13 Treatment of papillomavirus infections

Publications (1)

Publication Number Publication Date
NZ512850A true NZ512850A (en) 2004-01-30

Family

ID=3811858

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ512850A NZ512850A (en) 1998-12-11 1999-12-13 Treatment of papillomavirus infections

Country Status (12)

Country Link
US (2) US6867033B1 (cg-RX-API-DMAC7.html)
EP (1) EP1144005B1 (cg-RX-API-DMAC7.html)
JP (2) JP5274737B2 (cg-RX-API-DMAC7.html)
KR (1) KR100617485B1 (cg-RX-API-DMAC7.html)
AT (1) ATE344053T1 (cg-RX-API-DMAC7.html)
AU (1) AUPP765398A0 (cg-RX-API-DMAC7.html)
CA (1) CA2353866C (cg-RX-API-DMAC7.html)
DE (1) DE69933891T2 (cg-RX-API-DMAC7.html)
DK (1) DK1144005T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ512850A (cg-RX-API-DMAC7.html)
WO (1) WO2000035478A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA997638B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2284287T3 (es) * 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
AUPP765398A0 (en) 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
FR2802426B1 (fr) * 1999-12-15 2004-04-02 Neovacs Utilisation de proteines immunogenes immunosuppressives et/ou angiogeniques rendues inactives, pour la production d'iga secretoires
AUPR446801A0 (en) 2001-04-18 2001-05-17 University Of Queensland, The Novel compositions and uses therefor
EP1422526A1 (en) * 2002-10-28 2004-05-26 MTM Laboratories AG Method for improved diagnosis of dysplasias
WO2006113209A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
US10513541B2 (en) 2015-12-04 2019-12-24 Xiamen University Mutant of L1 protein of human papillomavirus type 11
WO2019081750A1 (en) * 2017-10-27 2019-05-02 Statens Serum Institut VACCINE AGAINST POLYGENIC INFLUENZA
WO2023196884A1 (en) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Detection assay for human papillomavirus (hpv) type 16 (hpv-16)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1359156B1 (en) 1991-07-19 2007-03-07 University of Queensland Vaccine against Human Papillomavirus (Type 18)
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
ES2264126T3 (es) * 1994-05-16 2006-12-16 MERCK & CO., INC. Vacunas contra el papilomavirus.
DE69531256T2 (de) * 1994-09-06 2004-05-27 Scan-Web I/S Verfahren und system zur herstellung von breiten, luftgelegten papierbahnen enthaltend ein absorbierendes pulver
AR004464A1 (es) 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
AU4258297A (en) 1996-09-11 1998-04-02 Merck & Co., Inc. Papillomavirus vaccine formulation
GB9621091D0 (en) * 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ES2273376T3 (es) 1996-12-20 2007-05-01 MERCK & CO., INC. Formulaciones de vacunas recombinantes frente a papilomas.
WO1998044944A2 (en) * 1997-04-08 1998-10-15 Merck & Co., Inc. Stabilized human papillomavirus formulations
DE19735118C1 (de) 1997-08-13 1998-08-13 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
AUPP765398A0 (en) 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties

Also Published As

Publication number Publication date
KR20010103711A (ko) 2001-11-23
JP2002532434A (ja) 2002-10-02
JP2011037902A (ja) 2011-02-24
ATE344053T1 (de) 2006-11-15
DK1144005T3 (da) 2007-03-05
US7172870B2 (en) 2007-02-06
WO2000035478A1 (en) 2000-06-22
CA2353866C (en) 2013-11-19
JP5274737B2 (ja) 2013-08-28
US20050244433A1 (en) 2005-11-03
ZA997638B (en) 2000-07-06
CA2353866A1 (en) 2000-06-22
DE69933891D1 (de) 2006-12-14
US6867033B1 (en) 2005-03-15
EP1144005A4 (en) 2005-02-09
EP1144005A1 (en) 2001-10-17
DE69933891T2 (de) 2007-06-21
KR100617485B1 (ko) 2006-09-01
AUPP765398A0 (en) 1999-01-14
EP1144005B1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
FI956014A0 (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
MY138883A (en) Use of asiatic acid for treatment of cencer
PL361389A1 (en) Effective antitumour treatments
EP1977760A3 (en) Method for treating human papillomavirus (HPV) infections
EP0869801A4 (en) THERAPEUTIC AND DIAGNOSTIC AGENTS FOR TREATING MICROBIAL INFECTIONS
NZ512659A (en) Use of growth hormone secretagogues for treatment of physical performance decline
AU7731700A (en) Low dose ifn-gamma for treatment of disease
AU2003210659A1 (en) Combination therapy for treatment of hiv infection
FR2725990B1 (fr) Derives hydrosolubles d'epipodophyllotoxine, leur procede de preparation, leur utilisation a titre de medicament, et leur utilisation destinee aux traitements anticancereux
ZA968783B (en) Flupirtine usage
MXPA02003742A (es) Tratamiento de tumores dermicos, verrugas e infecciones virales usando p. acnes muerto por calor.
MY124071A (en) Treatment of viral disease in swine
AU2450900A (en) Therapeutic nucleoside compound
AU2003253888A1 (en) Combination therapies with l-fmau for the treatment of hepatitis b virus infection
AP2003002852A0 (en) Natural antibodies active against HIV virus
AU5434899A (en) Cancer treatment
AU2211592A (en) Method of treatment for latent virus infection
AU2396900A (en) Treatment and prevention of hiv and other viral infections
AP2001002254A0 (en) Treatment of chronic viral infections with M. Vaccae.
WO2003059334A3 (en) Gemcitabine in the treatment of smallpox
GT199500023A (es) Formas de dosificacion de liberacion controlada azitromicina
UA32109A (uk) Спосіб пластики фарингоезофагостоми
UA32315A (uk) Спосіб накладання шкірного шва

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired